归芪三七口服液联合恩替卡韦在HBV相关性肝癌经动脉栓塞化疗中的临床应用价值-《西部中医药》

文章信息/Info

Title:: Clinical Application Value of GuiQi SanQi Oral Liquid and Entecavir Tablets to Transcatheter Arterial Chemoembolization in Treating HBV Related Hepatocellular Carcinoma

Author(s):: MA Yonghua, TANG Yubin; Jiayuguan Municipal the Second People′s Hospital, Jiayuguan 735100, China

Keywords:: transcatheter arterial chemoembolization (TACE); GuiQi SanQi oral liquid; entecavir tablets

摘要:: 目的：探讨归芪三七口服液联合恩替卡韦(ETV)在HBV相关性肝癌经动脉栓塞化疗(TACE)中的临床应用价值。方法：将80例患者随机分为对照组与治疗组各40例，2组均在行TACE治疗前始给予恩替卡韦治疗，治疗组在恩替卡韦治疗的同时加用归芪三七口服液治疗，行TACE治疗后1月监测血常规、肝脏功能、HBV DNA定量的变化情况。结果：治疗组血常规、肝脏功能的改善情况明显优于对照组（P＜0.05），但HBV DNA定量2组无明显差异(P＞0.05)。结论：归芪三七口服液联合恩替卡韦在HBV相关性肝癌行TACE治疗后，可以降低肝脏损害的严重程度，预防肝功能的进一步恶化。

Abstract:: Objective: To explore clinical application value of GuiQi SanQi oral liquid and entecavir tablets to transcatheter arterial chemoembolization (TACE) in treating HBV related hepatocellular carcinoma. Method: All 80 patients were randomized into the control group and the treatment group. Both groups took entecavir tablets before TACE was performed, and the treatment group were also given with GuiQi SanQi oral liquid, routine blood test, liver function and quantitative HBV DNA were monitored after TACE was performed in one month. Result: The improvements of routine blood test and liver function in the treatment group were superior to these of the control group (P＜0.05), but the comparison between both groups had insignificant difference in quantitative HBV DNA. Conclusion: GuiQi SanQi oral liquid and entecavir could reduce the severity of liver damage and prevent further deterioration of liver function in treating HBV related hepato cellular carcinoma.